A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer

This study looks at new ways to help patients with advanced breast cancer manage common side effects from a medication called capivasertib. By testing ways to prevent issues like diarrhea and skin rashes early on, researchers hope to make this life-extending treatment easier and more comfortable to take.

This trial is open to men and women aged 18 and older who have hormone-driven, HER2-negative breast cancer that has spread. Participants must be healthy enough to follow the study rules and cannot have certain other medical conditions or recent active cancer treatments.

You will receive a combination of cancer medications, including capivasertib and hormone therapy, along with extra medications to help prevent side effects. Throughout the study, your medical team will closely monitor your health to see if these preventive measures are working for you.

The study is currently open and recruiting new participants in New Haven, Connecticut. If you are interested, your local doctor can help determine if you are a good match for this specific location.